BY TIM WILLERT twillert@opubco.com
A Pennsylvania-based pharmaceutical company agreed Tuesday to pay $490.9 million, including $700,000 to Oklahoma, for unlawfully marketing the kidney transplant drug Rapamune, authorities said.
Wyeth Pharmaceuticals Inc., pleaded guilty in Oklahoma City federal court to a misdemeanor violation under the Federal Food, Drug and Cosmetic Act, and agreed to pay $233.5 million in criminal fines and forfeitures.
Additionally, the resolution includes civil settlements with the federal government and each of the 50 states totaling $257.4 million, about $700,000 of which will go to “repay loses” to Oklahoma's Medicaid program, Oklahoma City-based U.S. Attorney Sanford C. Coats announced at a midday news conference Tuesday.
“The FDA approved Rapamune for limited use in renal transplants and required the label to include a warning against certain uses,” Coats said.
Read more on NewsOK.com